What is CorWave?
Headquartered in Clichy, France, CorWave specializes in the engineering of next-generation cardiac assist devices. The company's core technology is designed to mimic the physiological flow of a healthy heart, addressing critical limitations found in traditional rotary pumps. By focusing on hemocompatibility and advanced fluid dynamics, CorWave is carving out a distinct market position as a leader in life-saving medical technology. The firm's trajectory from its initial Series A round to its current enterprise-level status reflects a sustained commitment to rigorous R&D and clinical validation, attracting top-tier life sciences investors who prioritize transformative healthcare solutions.
How much funding has CorWave raised?
CorWave has raised a total of $86.7M across 3 funding rounds:
Series A
$4M
Series B
$17.1M
Series C
$65.6M
Series A (2013): $4M with participation from G�rard Hasco�t
Series B (2016): $17.1M led by Novo Seeds, Sofinnova Partners, Bpifrance, Ysios Capital, and Seventure Partners
Series C (2023): $65.6M supported by Novo Holdings, Seventure Partners, EIC Fund, Bpifrance, Sofinnova Partners, and Ysios Capital
Key Investors in CorWave
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term value creation in the life sciences sector.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Ysios Capital
Ysios Capital is a prominent life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide to address high unmet medical needs.
What's next for CorWave?
With the recent influx of capital, CorWave is entering a pivotal phase of its lifecycle, transitioning from intensive research and development toward large-scale clinical trials and eventual commercialization. The strategic focus will likely center on regulatory milestones and the expansion of its manufacturing capabilities to meet anticipated demand. As the company scales, it will continue to leverage the deep industry expertise of its investor syndicate to navigate the complex regulatory environments of the European and North American markets. This growth trajectory suggests that CorWave is preparing to challenge established incumbents in the heart failure treatment space, potentially setting a new standard for patient outcomes in mechanical circulatory support.
See full CorWave company page
